Cancer treatments have traditionally involved a difficult balance between effectiveness and side effects. For skin cancers, this challenge is particularly pronounced. Researchers have worked to find ways to selectively target cancer cells while sparing healthy tissue, but progress has been limited by several persistent obstacles. Drug delivery systems typically lacked the precision needed to concentrate only in tumors.
